文献速递主动脉疾病

使用E-Tegra装置的腹主动脉腔内修复:多中心国家注册研究的初步结果

Endovascular Aortic Repair With the E-Tegra Device: Preliminary Outcomes From a Multicenter National Registry.
PubMed 文献 · J Endovasc Ther · 2024-08-27

TIGRE注册研究前瞻性纳入15个高容量中心2021年3月至2023年3月连续147例E-Tegra腹主动脉腔内修复(EVAR),其中90例至少1项解剖困难标准、25例超出装置IFU。中位随访20个月,无围手术期死亡及动脉瘤相关死亡,再干预5例;作者认为E-Tegra治疗标准及困难解剖腹主动脉瘤安全有效,但需更长期结局和更大样本量。

要点

  • TIGRE注册研究纳入147例E-Tegra EVAR,90例有解剖困难、25例超出IFU。
  • 技术成功率99.3%(146/147),辅助成功率100%,无围手术期死亡。
  • 中位随访20个月无动脉瘤相关死亡,再干预5例,标准与困难解剖间无差异。

核心结论

  • 作者认为E-Tegra治疗标准及困难解剖的腹主动脉瘤安全有效,并发症和再干预率低。
  • 作者指出需更长期结局和更大样本量以比较其与特定解剖标准相关的性能。

研究设计与样本

  • TIGRE为前瞻性维护数据库,纳入15个参与中心2021年3月至2023年3月连续E-Tegra EVAR病例。
  • 注册记录基线临床数据、腹主动脉解剖测量、围手术期及术后结局,计划随访3年。
  • 本文为截至2024年1月的初步分析,纳入147例连续EVAR(138例择期、9例急诊),其中7例联合髂动脉分支植入。

主要发现

  • 147例中90例至少1项解剖困难标准,25例在装置IFU外治疗。
  • 技术成功146例(99.3%),辅助成功147例(100%),无围手术期死亡。
  • 中位随访20个月无动脉瘤相关死亡。
  • 再干预5例:2例为IB型内漏,3例为II型内漏伴瘤囊增大;另5例II型内漏伴瘤囊稳定在观察中。
  • 标准解剖与困难解剖动脉瘤之间再干预无差异。

关键数值与推荐

  • 主要终点为技术和临床成功、围手术期死亡、免于内移植物破裂及主动脉相关死亡。
  • 次要终点为免于再干预及任何类型内漏(EL)。
  • 技术成功146/147(99.3%),辅助成功147/147(100%)。
  • 再干预5例,其中IB型内漏2例、II型内漏伴瘤囊增大3例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需更长期结局和更大样本量以比较其与特定解剖标准相关的性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Endovascular aortic repair (EVAR) is currently expanding its feasibility thanks to design innovations, but hostile proximal necks and narrow iliac arteries are still a constraint, as expressed by the Instructions for Use (IFU) of most devices. Our aim is to report the preliminary results of the E-Tegra endograft in infrarenal abdominal aortic aneurysms (AAAs) performed in 15 high-volume centers. MATERIALS AND METHODS: The e-Tegra Italian endoGraft REgistry (TIGRE) is a prospectively maintained database of consecutive EVAR with the E-Tegra stent-graft across 15 participating centers between March 2021 and March 2023. The registry records baseline clinical data, anatomic measurements of the abdominal aorta, perioperative and postoperative outcomes, with a scheduled follow-up period of 3 years for all patients. This is a preliminary analysis of the first results updated to January 2024. The primary endpoints are technical and clinical success, perioperative mortality, freedom from endograft rupture, and aortic-related mortality. The secondary endpoints are freedom from reintervention, and any type of endoleak (EL). The results were analyzed in relation with the anatomic characteristics of the AAAs, namely, iliac axes tortuosity and proximal neck hostility. RESULTS: The registry included 147 consecutive EVAR (138 elective and 9 in emergent setting), 7 of which were associated with an iliac branch implantation. Ninety patients had at least 1 criterion of anatomical hostility, and 25 were treated outside the device IFU. Primary technical success was achieved in 146 cases (99.3%) and assisted success in 147 (100%), with no perioperative mortality. After a median follow-up period of 20 months, no aneurysm-related mortality occurred. Reinterventions were 5: 2 for type IB EL and 3 for type II ELs with aneurysm sac increase. Five more type II ELs with aneurysm sac stability are under observation. No differences in terms of reinterventions were noted between aneurysms with standard and hostile anatomy. CONCLUSION: The E-Tegra endograft is safe and effective in treating AAAs with standard and hostile anatomy, with a low rate of complications and reinterventions, although longer-term outcomes and larger numbers are needed to compare its performances related to specific anatomic criteria.Clinical ImpactThis multi-center nationwide Registry reports a real-world experience of EVAR performed with the E-Tegra abdominal endograft across 15 high-volume Centers, providing early- and mid-term device-specific results, which will help vascular surgeons in endograft selection. In particular, this study focuses on clinical results obtained in treating aneurysms with hostile anatomy, analyzing the performances of the E-Tegra endograft in cases of hostile proximal necks and narrow or tortuous iliac axes.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Marone EM, Rinaldi LF, Brioschi C, et al. Endovascular Aortic Repair With the E-Tegra Device: Preliminary Outcomes From a Multicenter National Registry. J Endovasc Ther. 2024. PMID: 39188184. doi:10.1177/15266028241270861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。